{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:08:38Z","timestamp":1790402918278,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in LCH led to a targeted approach. However, targeted therapy cannot cure the disease, and cessation leads to quick relapses. Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission. Nineteen children were enrolled in the study: 13 were RO-positive (RO+) and 6 RO-negative (RO\u2013). Five patients received the therapy upfront, whereas the other 14 received it as a second or third line. The protocol starts with 28\u00a0days of vemurafenib (20\u00a0mg\/kg), which is followed by 3 courses of Ara-C and 2-CdA (100\u00a0mg\/m2 every 12 h, 6\u00a0mg\/m2 per day, days 1-5) with concomitant vemurafenib therapy. After that, vemurafenib therapy was stopped, and 3 courses of mono 2-CdA followed. All patients rapidly responded to vemurafenib: the median disease activity score decreased from 13 to 2 points in the RO+ group and from 4.5 to 0 points in the RO\u2013 group on day 28. All patients except 1 received complete protocol treatment, and 15 of them did not have disease progression. The 2-year reactivation\/progression-free survival (RFS) for RO+ was 76.9% with a median follow-up of 21\u00a0months and 83.3% with a median follow-up of 29\u00a0months for RO\u2013. Overall survival is 100%. Importantly, 1 patient experienced secondary myelodysplastic syndrome after 14\u00a0months from vemurafenib cessation. Our study demonstrates that combined vemurafenib plus 2-CdA and Ara-C is effective in a cohort of children with LCH, and the toxicity is manageable. This trial is registered at www.clinicaltrials.gov as NCT03585686.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009067","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T17:23:41Z","timestamp":1684776221000},"page":"5246-5257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E\u2013positive LCH"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-0624","authenticated-orcid":false,"given":"Dmitry","family":"Evseev","sequence":"first","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9968-9332","authenticated-orcid":false,"given":"Daria","family":"Osipova","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kalinina","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Raykina","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ignatova","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-2019","authenticated-orcid":false,"given":"Evelina","family":"Lyudovskikh","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Baidildina","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-6986","authenticated-orcid":false,"given":"Alexander","family":"Popov","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Zhogov","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1694","authenticated-orcid":false,"given":"Alexandra","family":"Semchenkova","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-5339","authenticated-orcid":false,"given":"Eugeny","family":"Litvin","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kotskaya","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-9634","authenticated-orcid":false,"given":"Ekaterina","family":"Cherniak","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Voronin","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3623-6547","authenticated-orcid":false,"given":"Eugeny","family":"Burtsev","sequence":"additional","affiliation":[{"name":"2Hematopoietic Stem Cell Transplantation Department, Morozov Children Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-3996","authenticated-orcid":false,"given":"Gleb","family":"Bronin","sequence":"additional","affiliation":[{"name":"2Hematopoietic Stem Cell Transplantation Department, Morozov Children Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9209-7238","authenticated-orcid":false,"given":"Irina","family":"Vlasova","sequence":"additional","affiliation":[{"name":"2Hematopoietic Stem Cell Transplantation Department, Morozov Children Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bazarma","family":"Purbueva","sequence":"additional","affiliation":[{"name":"3Hematology and Chemotherapy Department \u21161, Russian Children\u2019s Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-9379","authenticated-orcid":false,"given":"Olesya","family":"Fink","sequence":"additional","affiliation":[{"name":"3Hematology and Chemotherapy Department \u21161, Russian Children\u2019s Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-657X","authenticated-orcid":false,"given":"Ekaterina","family":"Pristanskova","sequence":"additional","affiliation":[{"name":"3Hematology and Chemotherapy Department \u21161, Russian Children\u2019s Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Dzhukaeva","sequence":"additional","affiliation":[{"name":"4Pediatric Hematology and Oncology Department, Piotrovich Regional Children Clinical Hospital, Khabarovsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Erega","sequence":"additional","affiliation":[{"name":"4Pediatric Hematology and Oncology Department, Piotrovich Regional Children Clinical Hospital, Khabarovsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Novichkova","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-0093","authenticated-orcid":false,"given":"Michael","family":"Maschan","sequence":"additional","affiliation":[{"name":"1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"25","key":"2023092213550040200_bib1","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2023092213550040200_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2023092213550040200_bib3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/pbc.22229","article-title":"2\u2032-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society","volume":"53","author":"Weitzman","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023092213550040200_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11538540-000000000-00000","article-title":"Multisystem Langerhans cell histiocytosis in children: current treatment and future directions","volume":"13","author":"Minkov","year":"2011","journal-title":"Paediatr Drugs"},{"issue":"12","key":"2023092213550040200_bib5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","article-title":"Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study","volume":"126","author":"Donadieu","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2023092213550040200_bib6","first-page":"880","article-title":"Front-line therapy of high-risk Langerhans cell histiocytosis with 2 chlordeoxyadenosine and cytosine arabinoside: an update of a single center experience","volume":"55","author":"Solopova","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023092213550040200_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.13475","article-title":"Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis","volume":"172","author":"Rosso","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2023092213550040200_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.13347","article-title":"Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning","volume":"169","author":"Veys","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2023092213550040200_bib9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2023092213550040200_bib10","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023092213550040200_bib11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023092213550040200_bib12","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2014.10.045","article-title":"Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis","volume":"73","author":"Haroche","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"31","key":"2023092213550040200_bib13","doi-asserted-by":"crossref","first-page":"22236","DOI":"10.18632\/oncotarget.25277","article-title":"Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature","volume":"9","author":"Heisig","year":"2018","journal-title":"Oncotarget"},{"issue":"31","key":"2023092213550040200_bib14","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023092213550040200_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12185-021-03205-8","article-title":"Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA","volume":"114","author":"Evseev","year":"2021","journal-title":"Int J Hematol"},{"issue":"16","key":"2023092213550040200_bib16","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2014-08-596080","article-title":"The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis","volume":"124","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023092213550040200_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-14-0742","article-title":"Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders","volume":"5","author":"Hyman","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"2023092213550040200_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14695","article-title":"Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis","volume":"178","author":"H\u00e9ritier","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2023092213550040200_bib19","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.3324\/haematol.2019.229187","article-title":"Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis","volume":"105","author":"Cui","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2023092213550040200_bib20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pbc.20160","article-title":"A\u00a0new clinical score for disease activity in Langerhans cell histiocytosis","volume":"43","author":"Donadieu","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2023092213550040200_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"16","key":"2023092213550040200_bib22","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon\u2019s two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat Med"},{"issue":"5","key":"2023092213550040200_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A\u00a0randomized trial of treatment for multisystem Langerhans\u2019 cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"2023092213550040200_bib24","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2023092213550040200_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"19","key":"2023092213550040200_bib26","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.2020005209","article-title":"Bone marrow\u2013derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis","volume":"136","author":"Xiao","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023092213550040200_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.17721","article-title":"A\u00a0circulating subset of BRAFV600E-positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors","volume":"194","author":"Poch","year":"2021","journal-title":"Br J Haematol"},{"issue":"7749","key":"2023092213550040200_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"15","key":"2023092213550040200_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","article-title":"Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition","volume":"133","author":"Eckstein","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2023092213550040200_bib30","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2021006229","article-title":"Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH","volume":"6","author":"Salek","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2023092213550040200_bib31","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/bloodadvances.2021006732","article-title":"Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis","volume":"7","author":"Milne","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023092213550040200_bib32","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2021005442","article-title":"Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis","volume":"6","author":"Eder","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2023092213550040200_bib33","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.26119","article-title":"Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis","volume":"96","author":"Goyal","year":"2021","journal-title":"Am J Hematology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5246\/2079940\/blooda_adv-2022-009067-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5246\/2079940\/blooda_adv-2022-009067-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:55:26Z","timestamp":1695390926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5246\/495968\/Vemurafenib-combined-with-cladribine-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009067","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}